Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been associated with interstitial nephritis neverthe...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammed Al Nuhait, Laila C. Abu Esba, Khalid Al Harbi, Meshary Al Meshary, Rami T. Bustami
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:International Journal of Pediatrics
Online Access:http://dx.doi.org/10.1155/2018/9256528
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549062716424192
author Mohammed Al Nuhait
Laila C. Abu Esba
Khalid Al Harbi
Meshary Al Meshary
Rami T. Bustami
author_facet Mohammed Al Nuhait
Laila C. Abu Esba
Khalid Al Harbi
Meshary Al Meshary
Rami T. Bustami
author_sort Mohammed Al Nuhait
collection DOAJ
description Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been associated with interstitial nephritis nevertheless; the combination of these agents has routinely been used for many years. However, there have been some observational studies that showed high rates of acute kidney injury (AKI) in patients receiving vancomycin and PTZ concomitant treatment compared to patients receiving vancomycin alone. The incidence of AKI in adult patients receiving vancomycin and PTZ concomitant treatment was reported in these studies to be relatively high. Similar studies in pediatric patients are lacking. Method. We conducted a single center retrospective chart review of 248 pediatric patients receiving one of the following treatments: vancomycin alone 36 patients, vancomycin/PTZ 62 patients, vancomycin/ceftazidime 99 patients, and vancomycin/ceftriaxone 51 patients. Result. Our results showed a low incidence of AKI in patients on vancomycin/PTZ concomitant treatment where overall incidence was only (4.8%) three cases and only one of them (2.0%) in a patient receiving the vancomycin/ceftriaxone concomitant treatment. No cases of AKI present in patients receiving vancomycin with ceftazidime or vancomycin alone. There were no statistically significant differences between the four treatment groups in terms of AKI incidence, vancomycin trough, and use of nephrotoxins. Conclusion. Overall, the incidence of AKI was low in our study sample with no statistically significant increased risk when PTZ was used in combination with vancomycin in a pediatric population. However, further investigation with an equal larger sample size is needed to confirm our findings.
format Article
id doaj-art-e0dc5f5f92034cf5a27e07459b8c4d92
institution Kabale University
issn 1687-9740
1687-9759
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series International Journal of Pediatrics
spelling doaj-art-e0dc5f5f92034cf5a27e07459b8c4d922025-02-03T06:12:17ZengWileyInternational Journal of Pediatrics1687-97401687-97592018-01-01201810.1155/2018/92565289256528Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care HospitalMohammed Al Nuhait0Laila C. Abu Esba1Khalid Al Harbi2Meshary Al Meshary3Rami T. Bustami4King Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaKing Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdul-Aziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaKing Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaCollege of Pharmacy, King Saud Bin Abdul-Aziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi ArabiaBackground. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been associated with interstitial nephritis nevertheless; the combination of these agents has routinely been used for many years. However, there have been some observational studies that showed high rates of acute kidney injury (AKI) in patients receiving vancomycin and PTZ concomitant treatment compared to patients receiving vancomycin alone. The incidence of AKI in adult patients receiving vancomycin and PTZ concomitant treatment was reported in these studies to be relatively high. Similar studies in pediatric patients are lacking. Method. We conducted a single center retrospective chart review of 248 pediatric patients receiving one of the following treatments: vancomycin alone 36 patients, vancomycin/PTZ 62 patients, vancomycin/ceftazidime 99 patients, and vancomycin/ceftriaxone 51 patients. Result. Our results showed a low incidence of AKI in patients on vancomycin/PTZ concomitant treatment where overall incidence was only (4.8%) three cases and only one of them (2.0%) in a patient receiving the vancomycin/ceftriaxone concomitant treatment. No cases of AKI present in patients receiving vancomycin with ceftazidime or vancomycin alone. There were no statistically significant differences between the four treatment groups in terms of AKI incidence, vancomycin trough, and use of nephrotoxins. Conclusion. Overall, the incidence of AKI was low in our study sample with no statistically significant increased risk when PTZ was used in combination with vancomycin in a pediatric population. However, further investigation with an equal larger sample size is needed to confirm our findings.http://dx.doi.org/10.1155/2018/9256528
spellingShingle Mohammed Al Nuhait
Laila C. Abu Esba
Khalid Al Harbi
Meshary Al Meshary
Rami T. Bustami
Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
International Journal of Pediatrics
title Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
title_full Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
title_fullStr Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
title_full_unstemmed Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
title_short Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
title_sort acute kidney injury in pediatric treated with vancomycin and piperacillin tazobactam in tertiary care hospital
url http://dx.doi.org/10.1155/2018/9256528
work_keys_str_mv AT mohammedalnuhait acutekidneyinjuryinpediatrictreatedwithvancomycinandpiperacillintazobactamintertiarycarehospital
AT lailacabuesba acutekidneyinjuryinpediatrictreatedwithvancomycinandpiperacillintazobactamintertiarycarehospital
AT khalidalharbi acutekidneyinjuryinpediatrictreatedwithvancomycinandpiperacillintazobactamintertiarycarehospital
AT mesharyalmeshary acutekidneyinjuryinpediatrictreatedwithvancomycinandpiperacillintazobactamintertiarycarehospital
AT ramitbustami acutekidneyinjuryinpediatrictreatedwithvancomycinandpiperacillintazobactamintertiarycarehospital